Goldman Sachs initiated coverage of Revolution Medicines (RVMD) with a Buy rating and $65 price target The firm says Revolution is a late stage clinical precision oncology company focused on developing a portfolio of RAS(On) inhibitors. Goldman sees blockbuster and underappreciated at current share levels commercial opportunities for the company.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines: Strategic Growth and Financial Stability Drive Buy Rating
- Revolution Medicines announces collaboration with Iambic
- Truist biotech analyst holds an analyst/industry conference call
- Biotech Alert: Searches spiking for these stocks today
- Promising Prospects for Revolution Medicines’ Daraxonrasib in Pancreatic Cancer Treatment